Logo

AZTA

Azenta, Inc.

AZTA

Azenta, Inc. • NASDAQ
$35.56 ▼ -1.96% (-0.71)
Market Cap $1.63 B
52w High $55.64
52w Low $23.91
Dividend Yield 0%
P/E 68.38
Volume 355.85K
Outstanding Shares 45.84M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $159.192M ▲ $70.373M ▲ $47.137M ▲ 29.61% ▲ $1.03 ▲ $1.901M ▼
Q3-2025 $143.942M ▲ $68.474M ▼ $-52.806M ▼ -36.686% ▼ $-1.15 ▼ $18.028M ▲
Q2-2025 $143.418M ▼ $82.037M ▲ $-40.456M ▼ -28.208% ▼ $-0.88 ▼ $1.382M ▼
Q1-2025 $147.51M ▼ $80.024M ▼ $-13.34M ▼ -9.043% ▼ $-0.29 ▼ $3.332M ▼
Q4-2024 $170.063M $81.706M $-4.984M -2.931% $-0.1 $13.421M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $340.92M ▲ $2.057B ▲ $333.608M ▼ $1.723B ▲
Q3-2025 $318.857M ▼ $2.019B ▼ $345.501M ▲ $1.674B ▼
Q2-2025 $328.339M ▼ $2.042B ▲ $340.433M ▲ $1.701B ▼
Q1-2025 $463.445M ▲ $2.041B ▼ $322.244M ▼ $1.719B ▼
Q4-2024 $462.091M $2.1B $331.074M $1.769B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $680K ▲ $25.81M ▲ $-29.701M ▲ $-128K ▲ $16.608M ▲ $14.971M ▲
Q2-2025 $-40.456M ▼ $13.573M ▼ $-137.842M ▼ $-5.154M ▼ $-125.571M ▼ $6.995M ▼
Q1-2025 $-13.34M ▼ $30.628M ▲ $76.256M ▼ $-5.126M ▲ $93.447M ▲ $22.048M ▲
Q4-2024 $-4.984M ▲ $13.711M ▲ $195.333M ▼ $-247.546M ▼ $-25.873M ▼ $1.658M ▲
Q3-2024 $-6.582M $1.791M $201.619M $-224.441M $-17.257M $-4.802M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $60.00M ▲$40.00M ▼$40.00M ▲$40.00M ▲
Service
Service
 $110.00M ▲$100.00M ▼$100.00M ▲$100.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Azenta’s revenue has been growing gradually over the last few years, but not at a rapid pace. The company consistently generates a healthy level of gross profit from its sales, which suggests its core services and products are valued and priced reasonably well. The main issue is further down the income statement: operating profit has been negative, and net income has remained in the red for several years. This points to high spending on things like research, technology, and overhead relative to the current scale of the business. Profitability briefly improved but then slipped back, which indicates that while the strategic direction may be sound, the cost structure and scale are not yet fully aligned to produce steady earnings. Overall, the income statement tells a story of a company in investment mode: growing, but still working to turn that growth into consistent, positive earnings for shareholders.

Balance Sheet

Balance Sheet Azenta’s balance sheet shows a business with a sizable asset base and a solid equity cushion built up over time. The company holds a meaningful amount of cash, even though its cash balance has come down from earlier peaks. This still provides a financial buffer to support ongoing investments, acquisitions, and innovation. Debt levels appear modest relative to the size of the business, suggesting low financial leverage and limited balance-sheet risk. Equity remains strong, although it has declined from earlier highs, likely reflecting past losses, portfolio changes, or capital returns. In simple terms, the company looks financially sturdy, with more flexibility than many peers to fund its strategy without relying heavily on borrowing.

Cash Flow

Cash Flow Cash generation has been uneven. A few years ago, operating cash flow dipped sharply into negative territory, which is often what you see in a company undergoing heavy investment or transition. More recently, operating cash flow has turned positive again, but only modestly so. Free cash flow has hovered around breakeven: slightly negative in some years and slightly positive in the most recent year. Capital spending has been steady, not excessive, which means the main swing factor is how efficiently Azenta converts its revenues into cash. The direction is encouraging—moving from a cash drain back toward self-funding—but the cash flow profile is not yet robust or deeply proven across different market conditions.

Competitive Edge

Competitive Edge Azenta occupies a specialized niche in life sciences by combining automated sample storage with advanced genomic and multiomics services. This integrated “from freezer to data” offering is a key competitive strength because customers can rely on a single partner across the full lifecycle of their samples, from long-term storage to high-end sequencing and analysis. Few competitors provide such a tightly connected ecosystem, which raises switching costs for customers and encourages long-term relationships. The company’s global footprint and deep scientific expertise further strengthen this position. On the other hand, Azenta still operates in highly competitive markets—both in lab automation and in genomic services—where technology is advancing quickly and pricing can be pressured. Its edge depends on staying ahead in automation, software integration, and specialized sequencing capabilities while continuing to demonstrate reliability at scale.

Innovation and R&D

Innovation and R&D Innovation is clearly at the core of Azenta’s strategy. The company has rolled out advanced automated storage systems like BioArc Ultra and Cryo Store Pico, which aim to improve energy efficiency, reduce manual handling, and bring high-end automation closer to the point of care. These products target both large repositories and smaller clinical or research settings, broadening the addressable market. On the genomics side, the GENEWIZ platform offers an extensive range of sequencing and multiomics services, including specialized capabilities for complex areas like AAV gene therapy. Proprietary sequencing protocols and partnerships, such as the collaboration with Form Bio to add AI-driven analysis, deepen its technical moat and could make its services more embedded in customers’ workflows. Management has also signaled ongoing investment in new facilities and tuck-in acquisitions, with expectations that today’s R&D pipeline will contribute more meaningfully to revenue in the coming years. The main risk is execution: the company must translate these innovations into scalable, profitable growth rather than just higher expenses.

Summary

Azenta looks like a life sciences tools and services company in the middle of an important transition. It has built a strong niche around automated sample management and genomics, with an integrated offering that many competitors cannot easily match. Its balance sheet and cash position provide room to continue investing in technology, geographic expansion, and selective acquisitions. At the same time, the financials highlight that this strategy is still a work in progress. Revenue is growing but not explosively, profitability remains negative, and cash generation is only just recovering from a period of significant investment. The business appears fundamentally sound and differentiated, but the central question going forward is whether Azenta can convert its technical and competitive strengths into sustained, profitable growth while keeping costs under control. In short: strategically interesting, financially still in the “build and prove” phase rather than the “steady, mature profitability” phase.

NEWS

November 21, 2025 · 6:30 AM UTC

Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025

Read more

November 12, 2025 · 4:05 PM UTC

Azenta Announces Fiscal 2025 Fourth Quarter and Full Year Conference Call and Webcast

Read more

November 4, 2025 · 4:05 PM UTC

Azenta Life Sciences Partners with PRECEDE Foundation to Advance Early Detection of Pancreatic Cancer

Read more

October 15, 2025 · 8:00 AM UTC

Azenta to Host Investor Day at its Biorepository Facility in Indianapolis, Indiana

Read more